Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth
leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage …

Context Whether prostate-specific membrane antigen positron emission tomography (PSMA-
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …

Background Molecular imaging is increasingly used to guide treatment decisions and
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …

Non-invasive assays for early cancer screening are hampered by challenges in the isolation
and profiling of circulating biomarkers. Here, we show that surface proteins from serum …

Background Despite revisions in 2005 and 2014, the Gleason prostate cancer (PCa)
grading system still has major deficiencies. Combining of Gleason scores into a three-tiered …

The early detection of cancer can significantly reduce cancer mortality and saves lives. Thus,
a great deal of effort has been devoted to the exploration of new technologies to detect early …

Background Imaging techniques are used to identify local recurrence of prostate cancer
(PCa) for salvage therapy and to exclude metastases that should be addressed with …

Background How best to treat rising prostate-specific antigen (PSA) concentration after
radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need …